GLP-1s and Gallstones: Understanding Your Gallbladder Risk

Last Updated: March 2026

The rapid and significant weight loss achieved with GLP-1 medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) can bring profound health benefits. However, this accelerated weight reduction also elevates the risk of certain side effects, notably problems with the gallbladder. In clinical trials, cholelithiasis, the medical term for gallstones, was reported in 1.6% of patients treated with semaglutide (Wegovy) compared to 1.1% for placebo, and in 1.4% of patients on tirzepatide (Zepbound) versus 1.0% for placebo [1, 2]. While these percentages may seem modest, understanding the underlying mechanisms and risk factors is crucial for anyone considering or currently using these medications.

The Gallbladder: A Small Organ with a Big Job

The gallbladder is a small, pear-shaped organ located just beneath your liver. Its primary function is to store and concentrate bile, a digestive fluid produced by the liver. Bile helps break down fats in the small intestine, facilitating their absorption. After a meal, especially one rich in fats, the gallbladder contracts, releasing concentrated bile into the small intestine through the bile ducts.

Gallstones form when substances in bile—primarily cholesterol and bilirubin—harden into small, pebble-like deposits. These can range in size from a grain of sand to a golf ball. While many people with gallstones experience no symptoms (a condition known as asymptomatic cholelithiasis), they can become problematic if they block the bile ducts, leading to pain, inflammation, or infection.

The Connection: GLP-1s, Rapid Weight Loss, and Gallstones

The link between GLP-1 medications and gallstones is complex, but current evidence overwhelmingly points to rapid weight loss itself as the primary mediator, rather than a direct toxic effect of the drug on the gallbladder. This phenomenon is not unique to GLP-1s; it’s a known complication of bariatric surgery and other aggressive weight loss interventions.

The U.S. Food and Drug Administration (FDA) acknowledges this mechanism, stating directly in the prescribing information for Wegovy: “Rapid weight loss can increase the risk of developing gallstones” [1].

Here’s how rapid weight loss contributes to gallstone formation:

1. Bile Supersaturation

When you lose weight rapidly, particularly when restricting calories and fat, your liver can alter the composition of bile. Specifically, it may secrete more cholesterol into the bile. This creates a state of “supersaturation,” where there’s too much cholesterol relative to bile salts, making it easier for cholesterol to crystalize and form stones.

2. Gallbladder Stasis (Reduced Motility)

GLP-1 receptor agonists have been shown to slow gastric emptying, which is one mechanism contributing to their efficacy in weight management. Some research suggests that these medications may also affect gallbladder motility, causing it to contract less frequently or less effectively. When the gallbladder doesn’t empty completely or regularly, bile can sit and stagnate, allowing more time for cholesterol crystals to grow into gallstones. A 2023 review in the British Journal of Clinical Pharmacology concluded that “the transient risk observed during the first 6 months of treatment likely stems from rapid weight loss and inhibited gallbladder motility” [4].

3. Increased Bile Sludge

Rapid weight loss can also lead to the formation of “bile sludge,” a thick mixture of cholesterol crystals, calcium salts, and mucus that can precede full-blown gallstones. This sludge can block ducts and cause symptoms even without discrete stones.

Quantifying the Risk: GLP-1 Trials vs. Placebo

To provide a clearer picture of the increased risk, let’s look at data from key clinical trials for the leading GLP-1 medications approved for weight management:

Sources: Wegovy Prescribing Information [1], Zepbound Prescribing Information [2]

A broader systematic review and meta-analysis published in JAMA Internal Medicine in 2022 analyzed data from 76 clinical trials involving over 100,000 patients. This comprehensive analysis found that GLP-1 receptor agonists were associated with a statistically significant increased risk of cholelithiasis (incidence rate ratio, 1.40) and cholecystitis (incidence rate ratio, 1.39) compared with placebo or other active comparators [3]. The authors calculated the number needed to harm (NNH) for cholelithiasis at 107 and for cholecystitis at 169, meaning that for every 107 people treated, one additional case of cholelithiasis would occur, and for every 169 people treated, one additional case of cholecystitis would occur.

Understanding Your Individual Risk Factors

While the overall risk increase is moderate, certain individuals may be more susceptible to developing gallstones while on GLP-1 medications. Recognizing these risk factors is paramount:

• Pre-existing Gallstones or History of Gallbladder Disease: If you’ve had gallstones before, or a family history of them, your risk is significantly higher.
• Rapid Weight Loss Rate: Losing weight very quickly, often defined as more than 2 kg (approximately 4.4 pounds) per month, is a primary risk factor regardless of the method. GLP-1s are highly effective at facilitating this rate of loss.
• Female Sex: Women are generally more prone to gallstones than men, especially those who have had multiple pregnancies.
• Age: The risk of gallstones increases with age.
• Ethnicity: Certain ethnic groups, such as Native Americans and Mexican Americans, have a higher prevalence of gallstones.
• Dietary Factors: A diet high in fat and cholesterol, and low in fiber, can contribute to gallstone formation, though this interaction with GLP-1s specifically is still being studied.
• Diabetes and Insulin Resistance: Individuals with type 2 diabetes or insulin resistance are at an elevated baseline risk for gallstones.

Recognizing the Symptoms of Gallbladder Problems

It’s important to be vigilant for symptoms that might indicate gallstones or gallbladder inflammation (cholecystitis) while on a GLP-1 medication. These symptoms can range from mild discomfort to severe pain requiring emergency medical attention.

Common symptoms include:

• Biliary Colic: This is the most common symptom, characterized by sudden and rapidly intensifying pain in the upper right part of your abdomen. The pain can also radiate to your back or right shoulder blade. It often occurs after eating fatty meals and can last from 30 minutes to several hours.
• Nausea and Vomiting: Often accompanying the abdominal pain.
• Fever and Chills: May indicate inflammation or infection (cholecystitis).
• Jaundice: A yellowing of the skin and whites of the eyes, which occurs if a gallstone blocks the common bile duct, preventing bile from reaching the intestine and causing it to back up into the liver and bloodstream.
• Dark Urine and Clay-Colored Stools: Also signs of bile duct obstruction.
• Bloating and Indigestion: Though less specific, these can sometimes be associated with gallbladder issues.

If you experience severe, persistent abdominal pain, fever, jaundice, or severe nausea and vomiting, seek immediate medical attention. These could be signs of acute cholecystitis, cholangitis (bile duct infection), or even biliary pancreatitis, which is inflammation of the pancreas caused by a gallstone blocking its duct.

Mitigation and Prevention Strategies

While you can’t entirely eliminate the risk, particularly if you’re experiencing significant weight loss, there are strategies to consider that may help mitigate the risk of gallstones while on GLP-1 medications:

• Gradual Weight Loss: While GLP-1s are designed for rapid loss, ensuring your weight loss isn’t too aggressive, especially exceeding 4.4 lbs (2 kg) per month, can be beneficial where possible. This is a delicate balance, as the efficacy of GLP-1s often hinges on their ability to induce substantial weight reduction.
• Dietary Considerations:
  • Balanced Diet: Focus on a diet rich in fruits, vegetables, and whole grains.
  • Healthy Fats: While avoiding overly fatty meals can help prevent biliary colic attacks if you already have gallstones, drastically reducing fat intake during rapid weight loss might not prevent gallstone formation and could potentially worsen bile stagnation. Aim for moderate intake of healthy fats.
  • Hydration: Staying well-hydrated is always beneficial for overall health, including digestive processes.
• Regular Monitoring:
  • Clinician Vigilance: Your prescribing clinician should be aware of the potential for gallbladder issues and monitor for symptoms, especially during the initial months of treatment when the most rapid weight loss typically occurs.
  • Baseline Assessment: For individuals with significant risk factors (e.g., prior gallstones, family history, very rapid weight loss goals), some clinicians may consider a baseline ultrasound of the gallbladder before initiating GLP-1 therapy. This is not routine practice but may be discussed for high-risk individuals.
• Prophylactic Medications: In specific high-risk scenarios (e.g., after bariatric surgery), ursodeoxycholic acid (ursodiol) is sometimes prescribed to prevent gallstone formation by modifying bile composition. The routine use of ursodiol for GLP-1 associated weight loss is not standard but could be considered on a case-by-case basis under medical guidance.
• Elective Cholecystectomy: For individuals with very high pre-existing risk (e.g., known asymptomatic gallstones causing recurrent issues, or a strong family history with severe prior events), elective gallbladder removal (cholecystectomy) before starting GLP-1 therapy might be discussed, though this is a significant surgical intervention and not a routine recommendation.

What Happens if Gallstones Develop?

If you develop symptomatic gallstones, treatment options depend on the severity and frequency of symptoms.

• Observation: For asymptomatic gallstones, often no treatment is needed, but monitoring for symptoms is important.
• Medications: Ursodeoxycholic acid can sometimes dissolve certain types of gallstones over many months or years, but it’s not effective for all